CLOVIS ONCOLOGY INC (CLVS)

Company Profile

Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. The company is headquartered in Boulder, Colorado and currently employs 413 full-time employees. The company went IPO on 2011-11-16. The firm is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and additional international markets. Its segments include U.S. and ex-U.S. Its product, Rubraca, is an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP) marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer and an indication specific to metastatic castration-resistant prostate cancer (mCRPC). Its FAP-2286, is an investigational diagnostic and therapeutic agent targeting fibroblast activation protein (FAP). The company also provides Lucitanib, which is an investigational, oral, potent angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3), platelet-derived growth factor receptors alpha and beta (PDGFR α/β) and fibroblast growth factor receptors 1 through 3 (FGFR1-3).

Company Info

CLOVIS ONCOLOGY INC

Suite 100, 2525 28Th Street

Boulder COLORADO 80301

P: 13036255000.0

CEO: Patrick J. Mahaffy

Employees: 413

Website: https://clovisoncology.com/